Good day,
Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Before we send you your first edition, please take a moment to confirm your subscription below. We will not be able to send your newsletter until you confirm your subscription.
Confirm Your Subscription Here
The Earnings360 Team
Saturday's Bonus News Growth Picks: 3 Low-Cost Stocks That Could Double in ValueWritten by Chris Markoch. Published 10/27/2025. 
Key Points - Three undervalued growth stocks trading under $50 could deliver major upside if market conditions strengthen in 2026.
- Equinox Gold, Birkenstock, and Immunocore each carry analyst price targets suggesting 50% to 100% potential gains.
- Rising institutional interest, improving earnings, and biotech innovation make these stocks compelling buy-and-hold opportunities.
Many stocks are objectively overvalued, which makes it difficult for investors to find names with the potential to double. Penny stocks (stocks trading below $5) are often suggested, but their risk‑reward profile typically suits only very risk‑tolerant, nimble investors. Still, opportunities exist. One way to surface them is by looking at analyst sentiment. Analysts don't always get it right, but they often have access to data and company resources that retail investors lack, so their views can be useful when doing due diligence. While everyone's chasing the same AI plays, George Gilder is focused on something completely different.
He says a 4-nanometer device that's 80 MILLION times more powerful than the chip he gave Reagan is now being made in America for the first time.
And he's identified 3 companies that control this technology. Get the details before this BOMBSHELL announcement changes everything. With that in mind, here are three stocks trading under $50 per share that analysts see with significant upside potential. While analysts aren't necessarily predicting a doubling in every case, consensus price targets are close enough that each could double if the broader economy and company fundamentals cooperate. Equinox Gold: Gold's Momentum Could Keep Running Equinox Gold Corp. (NYSEAMERICAN: EQX) is a Canadian gold miner. As of Oct. 27, EQX stock is up about 100% year-to-date, yet analysts list a consensus price target of $26 — more than 149% above its current level. Equinox is essentially a play on the surge in gold prices. Many analysts view mining stocks like EQX as a leveraged way for equity investors to benefit from rising gold. The most bullish forecasts even see the spot price of gold approaching $5,000 before the end of 2025, with potential for further gains in 2026. Higher spot prices improve Equinox's margins and profitability; the main risk is an unwind in the gold trade. Institutional ownership of EQX is only about 38%, but it has been climbing sharply over the past 12 months and rising for more than two years — a trend some investors find encouraging. Birkenstock: A Consumer Stock Ready to Rebound It's been a tough year for consumer discretionary names like Birkenstock Group AG (NYSE: BIRK). BIRK is down roughly 25% in 2025, but the company may be getting lumped in with a weak retail sector despite solid underlying positioning. Birkenstock's year‑over‑year revenue and earnings are higher, with double‑digit revenue growth across segments and channels. Analysts expect earnings to rise more than 26% over the next 12 months, which aligns with a forward price‑to‑earnings (P/E) ratio near 23x. Another potentially attractive feature is BIRK's short interest, around 17%. That figure has fallen in the past month, which could indicate short sellers are easing exposure — and it still leaves room for a short squeeze if the shares rally sharply. Analysts' consensus price target for BIRK is $68.38, implying roughly 58% upside. The company reports third‑quarter results on Dec. 17, and strong holiday sales could help lift the stock into 2026. Immunocore: Biotech With Breakthrough Potential Immunocore plc (NASDAQ: IMCR) is a biotechnology company developing cancer treatments using T‑cell technology. As of August 2025, the company has one drug that has successfully completed clinical trials and three candidates in or entering Phase 3 trials. Biotech names are often cited for their doubling potential: the business case can be straightforward — if a company gets a drug through trials and to market, its stock can re-rate materially. Immunocore is now generating measurable revenue and appears to be moving toward profitability. Analysts peg IMCR at a consensus price target of $61, though HC Wainwright reiterated a Buy on Oct. 22 with a $100 target. Not all analysts share that bullish view. Weiss Research rates the stock a Sell, arguing that much of the company's growth is already priced into the shares.
| 
